Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
15.26
-0.22 (-1.42%)
Oct 12, 2026, 1:32 PM EDT - Market open
Ultragenyx Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 717 | 673 | 560 | 434 | 363.33 | 351.41 | |
Revenue Growth | 17.51% | 20.18% | 29.03% | 19.45% | 3.39% | 29.66% |
Cost of Revenue | 866 | 859 | 775 | 693 | 734.11 | 513.16 |
Gross Profit | -149 | -186 | -215 | -259 | -370.78 | -161.76 |
Selling, General & Admin | 349 | 349 | 321 | 310 | 278.14 | 219.98 |
Operating Expenses | 349 | 349 | 321 | 310 | 278.14 | 219.98 |
Operating Income | -498 | -535 | -536 | -569 | -648.92 | -381.74 |
Interest Expense | -77 | -62 | -63 | -66 | -43.02 | -29.42 |
Interest & Investment Income | 23 | 25 | 37 | 27 | 11.07 | 1.93 |
Other Non Operating Income (Expenses) | - | 1 | -5 | -1 | -1.57 | -1.69 |
EBT Excluding Unusual Items | -552 | -571 | -567 | -609 | -682.43 | -410.92 |
Merger & Restructuring Charges | -30 | - | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -19.3 | -42.06 |
Pretax Income | -582 | -571 | -567 | -609 | -701.73 | -452.98 |
Income Tax Expense | 4 | 4 | 2 | -2 | 5.7 | 1.04 |
Net Income | -586 | -575 | -569 | -607 | -707.42 | -454.03 |
Net Income to Common | -586 | -575 | -569 | -607 | -707.42 | -454.03 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 101 | 99 | 91 | 74 | 70 | 68 |
Shares Outstanding (Diluted) | 101 | 99 | 91 | 74 | 70 | 68 |
Shares Change | 4.21% | 8.95% | 23.13% | 5.13% | 3.13% | 11.42% |
EPS (Basic) | -5.83 | -5.83 | -6.29 | -8.26 | -10.12 | -6.70 |
EPS (Diluted) | -5.83 | -5.83 | -6.29 | -8.26 | -10.12 | -6.70 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -489 | -472 | -421 | -519 | -496.59 | -411.79 |
Free Cash Flow Per Share | -4.86 | -4.79 | -4.65 | -7.06 | -7.10 | -6.07 |
Gross Margin | -20.78% | -27.64% | -38.39% | -59.68% | -102.05% | -46.03% |
Operating Margin | -69.46% | -79.50% | -95.71% | -131.11% | -178.60% | -108.63% |
Profit Margin | -81.73% | -85.44% | -101.61% | -139.86% | -194.70% | -129.20% |
Free Cash Flow Margin | -68.20% | -70.13% | -75.18% | -119.59% | -136.68% | -117.18% |
EBITDA | -465 | -500 | -500 | -543 | -630.7 | -368.5 |
EBITDA Margin | -64.85% | -74.29% | -89.29% | -125.11% | -173.59% | -104.86% |
D&A For EBITDA | 33 | 35 | 36 | 26 | 18.22 | 13.24 |
EBIT | -498 | -535 | -536 | -569 | -648.92 | -381.74 |
EBIT Margin | -69.46% | -79.50% | -95.71% | -131.11% | -178.60% | -108.63% |
Revenue as Reported | 717 | 673 | 560 | 434 | 363.33 | 351.41 |